PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Sachs, S. ; Niu, L.* ; Geyer, P.* ; Jall, S. ; Kleinert, M. ; Feuchtinger, A. ; Stemmer, K. ; Brielmeier, M. ; Finan, B.* ; DiMarchi, R.D.* ; Tschöp, M.H. ; Wewer Albrechtsen, N.* ; Mann, M.* ; Müller, T.D. ; Hofmann, S.M.

Plasma proteome profiles treatment efficacy of incretin dual agonism in diet-induced obese female and male mice.

Diabetes Obes. Metab. 23, 195-207 (2021)
Verlagsversion Forschungsdaten DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
Aims Unimolecular peptides targeting the receptors for glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) (GLP-1/GIP co-agonist) have been shown to outperform each single peptide in the treatment of obesity and cardiometabolic disease in preclinical and clinical trials. By combining physiological treatment endpoints with plasma proteomic profiling (PPP), we aimed to identify biomarkers to advance non-invasive metabolic monitoring of compound treatment success and exploration of ulterior treatment effects on an individual basis.Materials and methods We performed metabolic phenotyping along with PPP in body weight-matched male and female diet-induced obese (DIO) mice treated for 21 days with phosphate-buffered saline, single GIP and GLP-1 mono-agonists, or a GLP-1/GIP co-agonist.Results GLP-1R/GIPR co-agonism improved obesity, glucose intolerance, non-alcoholic fatty liver disease (NAFLD) and dyslipidaemia with superior efficacy in both male and female mice compared with mono-agonist treatments. PPP revealed broader changes of plasma proteins after GLP-1/GIP co-agonist compared with mono-agonist treatments in both sexes, including established and potential novel biomarkers for systemic inflammation, NAFLD and atherosclerosis. Subtle sex-specific differences have been observed in metabolic phenotyping and PPP.Conclusions We herein show that a recently developed unimolecular GLP-1/GIP co-agonist is more efficient in improving metabolic disease than either mono-agonist in both sexes. PPP led to the identification of a sex-independent protein panel with the potential to monitor non-invasively the treatment efficacies on metabolic function of this clinically advancing GLP-1/GIP co-agonist.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
6.577
1.479
5
8
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Bariatric Surgery ; Combinatorial Pharmacology ; Incretins ; Obesity ; Plasma Proteomics; Receptor Agonist; Biomarkers; Disease; Homeostasis; Expression; C57bl/6j; Gip
Sprache englisch
Veröffentlichungsjahr 2021
Prepublished im Jahr 2020
HGF-Berichtsjahr 2020
ISSN (print) / ISBN 1462-8902
e-ISSN 1463-1326
Zeitschrift Diabetes, Obesity and Metabolism
Quellenangaben Band: 23, Heft: 1, Seiten: 195-207 Artikelnummer: , Supplement: ,
Verlag Wiley
Verlagsort 111 River St, Hoboken 07030-5774, Nj Usa
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Diabetes and Regeneration Research (IDR)
Institute of Diabetes and Obesity (IDO)
CF Pathology & Tissue Analytics (CF-PTA)
CF Comparative Medicine (AVM)
POF Topic(s) 30201 - Metabolic Health
90000 - German Center for Diabetes Research
30505 - New Technologies for Biomedical Discoveries
30202 - Environmental Health
Forschungsfeld(er) Helmholtz Diabetes Center
Enabling and Novel Technologies
Genetics and Epidemiology
PSP-Element(e) G-502390-001
G-501900-221
G-502200-001
A-630600-001
G-500900-001
Förderungen Helmholtz Zentrum Munchen
Deutsche Forschungsgemeinschaft
European Research Council
Helmholtz Alliance ICEMED
Helmholtz cross-program topic "Metabolic Dysfunction"
Helmholtz Initiative on Personalized Medicine iMed
Initiative and Networking Fund of the Helmholtz Association
Research Foundation
Novo Nordisk Foundation
Alexander von Humboldt-Stiftung
DOI 10.1111/dom.14215
WOS ID WOS:000585922500001
Scopus ID 85096748630
PubMed ID 33001570
Erfassungsdatum 2020-11-18
[➜Korrektur melden]